Eylea
Phase 3Small molecule
BayerEylea is used to treat eye diseases that cause vision loss, particularly age-related macular degeneration and diabetic retinopathy, by reducing abnormal blood vessel growth in the eye.[1] Eylea is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Eylea is one of 63 small molecule programs targeting Wet Age-Related Macular Degeneration. It is currently in Phase 3.
3
Indications
28
Total Trials
3
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Zometa
PfizerApproved
Bayer Aspirin
BayerApproved
Tecfidera
BiogenApproved
Plavix
SanofiApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration8 trials
Show 5 more trials
Diabetic Macular Edema4 trials
Show 1 more trial
Wet Age-Related Macular Degeneration3 trials
Neovascular AMD2 trials
10 more indications
Polypoidal choroidal vasculopathy1 trial
Efficacy1 trial
Effectiveness1 trial
Diabetic Macular Oedema1 trial
Efficacy and Safety1 trial
Quality of Life1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eylea. EMBL-EBI & Wellcome Sanger Institute.
- [4]